S. Thoelen

发表

The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.

G. Moens, G. Leroux-Roels, I. Desombere, 2002, Vaccine.

Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody.

R. Dagan, A. Safary, S. Ashkenazi, 2000, The Pediatric infectious disease journal.

The first combined vaccine against hepatitis A and B: an overview.

P. van Damme, G. Leroux-Roels, A. Safary, 1999, Vaccine.

Long-term persistence of cellular immunity towards hepatitis A virus following hepatitis A virus vaccination

K. Herck, G. Leroux-Roels, I. Desombere, 2002 .

Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trial.

R. Frenck, J. Poolman, B. Spiessens, 2019, The Lancet. Infectious diseases.

Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system.

P. van Damme, G. Leroux-Roels, A. Meheus, 1998, Vaccine.

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results.

P. van Damme, A. Meheus, K. Van Herck, 1998, Vaccine.

Single dose inactivated hepatitis A vaccine: Rationale and clinical assessment of the safety and immunogenicity

P Van Damme, F E André, P. van Damme, 1994, Journal of medical virology.

Comparison of the reactogenicity and immunogenicity of a two injection combined high-dose hepatitis A and hepatitis B vaccine to those of Twinrix.

B. Genton, Gilbert GREUB, A. Safary, 2000, Vaccine.

A hepatitis B vaccine formulated with a novel adjuvant system.

G. Leroux-Roels, M. Kundi, I. Desombere, 2000, Vaccine.

Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long‐term antibody persistence

P Van Damme, P. van Damme, A. Meheus, 1994, Journal of medical virology.

Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.

E. Bernasconi, J. Poolman, S. Harbarth, 2017, The Lancet. Infectious diseases.

2712. Safety and Immunogenicity of two Doses of ExPEC4V Vaccine Against Extraintestinal Pathogenic Escherichia coli Disease in Healthy Adult Participants

J. Poolman, B. Spiessens, W. Haazen, 2019, Open Forum Infectious Diseases.

Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants

H. Tamura, J. Poolman, Yuki Saito, 2018, Human vaccines & immunotherapeutics.

An overview on a novel adjuvanted prophylactic hepatitis B vaccine.

S. Thoelen, 2000, Acta gastro-enterologica Belgica.

Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years.

P. van Damme, K. Van Herck, S. Thoelen, 1999, Scandinavian journal of gastroenterology.

The safety, reactogenicity and longterm immunogenicity of two lots of an inactivated hepatitis A vaccine

A. Meheus, A. Safary, P. Damme, 1993 .

A prophylactic hepatitis B vaccine with a novel adjuvant system.

N. Tornieporth, N. De Clercq, S. Thoelen, 2001, Vaccine.

Reactogenicity and Immunogenicity of a Combined Hepatitis A and B Vaccine in Healthy Adults

A. Meheus, A. Safary, P. Damme, 1994 .

Long-term immunogenicity of a high potency inactivated hepatitis A vaccine

K. Herck, A. Meheus, P. Damme, 1998 .